Custirsen
- Generic Name
- Custirsen
- Drug Type
- Biotech
- CAS Number
- 890056-27-6
- Unique Ingredient Identifier
- L26E95NLRK
- Background
Custirsen is a benzopyran with potential antineoplastic activity. Custirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor-related mechanisms. Custirsen is also being investigated in the treatment of primary brain tumors.
- Indication
Investigated for use/treatment in brain cancer and breast cancer.
Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas
- Conditions
- GlioblastomaMalignant Gliomas
- First Posted Date
- 2003-12-19
- Last Posted Date
- 2007-01-04
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT00074646
- Locations
- 🇺🇸
Neuro Oncology BranchNational Cancer Institute, Bethesda, Maryland, United States
CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00074243
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 25
- Registration Number
- NCT00054106
- Locations
- 🇨🇦
British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.